PremiumThe FlyIGC Pharma expands CALMA clinical trial IGC Pharma announces interim data from Phase 2 trial of IGC-AD1 IGC Pharma announces additional interim results from IGC-AD1 trial PremiumThe FlyIGC Pharma reports Q3 EPS (2c) vs. (9c) last year IGC Pharma launches Holiby wellness brand Is IGC a Buy, Before Earnings? PremiumThe FlyRising High: Innovative Industrial reports PharmaCann default Rising High: Exclusive talk with biopharma company HMNC Brain Health Rising High: Organigram acquires Motif Labs for C$90M upfront 
